The Icos Alumni: Where Are They Now?
Luke Timmerman11/18/09Comments (4)Follow @ldtimmerman
(Page 2 of 9)
—Mike Bradley, staff scientist, Array Biopharma
—Heather Brammer, quality assurance manager, ZymoGenetics
—Mike Brandenstein, scientist, Amgen
—Jacqueline Brassard, scientific director, pathology, Allergan
—Heather (Brand) Brett, scientist, Amgen
—Jeff Bridewell, thought leader liaison, Genentech
—Doug Burns, principal, DBC Consulting
—Katie Carrigan, director of human resources, ZymoGenetics
—Jason Carstens, director of process development, CMC Icos
—Shannon Carstens, principal product quality leader, Amgen
—Allen Casey, group leader, high throughput screening/robotics, Infectious Disease Research Institute
—Sommer Castro, research technician, Fred Hutchinson Cancer Research Center
—Tina Catterall, managing partner, Global Interactions
—Shannon Cavallari, training coordinator, PATH
—Shing Chang, R&D director, Drugs for Neglected Diseases Initiative
—David Chantry, senior scientist, Genentech
—Jay Charleston, owner and principal, STNW Consulting, owner of Stereotome NW
—Hao Chen, principal scientist, Calistoga Pharmaceuticals
—Janice Chittenden, director of software quality, NeuroVista
—Michael Cicirelli, scientist, Theraclone Sciences
—Paul Clark, operating partner, Genstar Capital, member of board of directors at Amylin Pharmaceuticals
—Courtney Clark, research associate II, Seattle Genetics
—Darcey Clark, senior scientist, Amgen [Updated: 12:20 pm Pacific, 3/29/10]
—Tony Colasin, consultant, APC Corporate Development & Strategy Consulting
—Anita Colvin, technical scientist, CMC Icos
—Tom Cox, senior associate scientist, Novo Nordisk
—David Crowe, scientist, Mirina
—Dee Czaykowski, life sciences consultant [Added 12/30/09]
—Jeff Dantzler, senior research associate, Novo Nordisk
—Bela Denes, senior director of clinical research and development, Spectrum Pharmaceuticals
—Peter de Vries, associate director of translational sciences, Ikaria
—Mike Deeley, consultant, Somerset Consulting … Next Page »
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Johnny T. Stine
11/18/09 1:48 pm
I actually loved our logo – very simple, but it just looked like fun.
When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.
By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)
Luke Timmerman
11/18/09 2:04 pm
Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.
I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?
David Miller
11/23/09 2:54 pm
Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.
Abby Kliphardt
3/3/10 10:19 am
Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….